Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. Additionally we are shipping Somatostatin Receptor 2 Antibodies (83) and Somatostatin Receptor 2 Proteins (7) and many more products for this protein.
Showing 7 out of 11 products:
SSTR2 was significantly hypermethylated in colorectal cancer tissues when compared with adjacent normal colorectal tissues.
This study investigated the presence of progenitor/stem cells in non-functioning pituitary tumors (NFPTs) and tested the efficacy of dopamine receptor type 2 (DRD2 (show DRD2 ELISA Kits)) and somatostatin receptor type 2 (SSTR2) agonists to inhibit in vitro proliferation
expression of MDM2 (show MDM2 ELISA Kits), somatostatin (show SST ELISA Kits) receptor 2A, and PD-L1 (show CD274 ELISA Kits) in follicular dendritic cell sarcoma
Combination treatment increased both SSTR2 and SSTR5 (show SSTR5 ELISA Kits) mRNA and protein levels in DU-145 cells. The data suggest that this combination therapy may be a good candidate for patients with advanced metastatic Prostate cancer (PCa (show FLVCR1 ELISA Kits)) do not respond to androgen deprivation.
although the limited number of cases with adequate term follow-up, SSTR (show SSTR3 ELISA Kits)-2A expression could be a prognostic factor and somatostatin (show SST ELISA Kits) analogs therapeutic candidate for SmCCs of the bladder as these tumors show high percentage of SSTR (show SSTR3 ELISA Kits)-2A expression
SSTR2 expression was tested in GH-secreting adenomas from 60 patients with acromegaly who had undergone pituitary surgery, 36 of whom had received octreotide with varying levels of response. Its expression was not correlated with baseline or post-octreotide GH or IGF-1 (show IGF1 ELISA Kits) levels or tumor volume.
Filamin-A (show FLNA ELISA Kits) is required to mediate SSTR2 effects in pancreatic neuroendocrine tumours
Data showed that the distribution of somatostatin (show SST ELISA Kits) receptor (SSTR (show SSTR3 ELISA Kits)) subtypes among the 199 pancreatic neuroendocrine tumors (PNETs) was: SSTR2 (54.8%), SSTR1 (show SSTR1 ELISA Kits) (53.3%), SSTR4 (show SSTR4 ELISA Kits) (51.8%), SSTR5 (show SSTR5 ELISA Kits) (33.7%), and SSTR3 (show SSTR3 ELISA Kits) (28.6%).
SSTR2 promoter hypermethylation might be associated with the risk and progression of laryngeal squamous cell carcinoma in males.
VPA was observed to stimulate the expression of somatostatin receptor type 2 (SSTR2).
Loss of sst2 from pancreatic tissues activates PI3K signaling via AKT (show AKT1 ELISA Kits), leading to activation of NF-kappaB (show NFKB1 ELISA Kits), amplification of oncogenic KRAS signaling, increased expression of CXCL16 (show CXCL16 ELISA Kits), and pancreatic tumor formation.
The expression and localization of the three receptors (SSTR3 (show SSTR3 ELISA Kits)-SSTR5 (show SSTR5 ELISA Kits)) in wild-type (WT), single-knockout (SSTR1 (show SSTR1 ELISA Kits) KO) and double-knockout SSTR1 (show SSTR1 ELISA Kits)/SSTR2 (DKO) mice, are reported.
SST2 expression protects against gentamicin-induced auditory hair cell loss in the mammalian inner ear.
Knock-down of SSTR2 leads to loss of pluripotency in murine embryonic stem cells.
Inhibition of the Sstr2 receptor reversed the anticonvulsant effect mediated by cortistatin-14 (show CORT ELISA Kits).
OCT-P407 induces mRNA expression of SSTR-2 and caspase-3 and decreases that of VEGF in mice.
The study encourages the use of liver tissue SSR2 (show SSR2 ELISA Kits) protein and mRNA as a reliable tumor marker for liver cancer
when activated by SST (show SST ELISA Kits)-14, SSTR2A internalizes and recycles via the Golgi, which requires ECE-1 (show ECE1 ELISA Kits) degradation of SST (show SST ELISA Kits)-14 and receptor dissociation from beta-arrestins
Findings suggest that somatostatin (show SST ELISA Kits) and its receptors (SSTR2 and SSTR5 (show SSTR5 ELISA Kits)) are important markers in the regulation and development of Sertoli cell.
The aim of this study was to validate an animal model expressing SSTR2 and to correlate the immunohistochemical (IHC) analysis with (18)F-FDG (show SMUG1 ELISA Kits) and (68)Ga-DOTATOC uptake in vivo.
Follicle-stimulating hormone regulates the SSTR2 protein expression in bovine granulosa cells.
SRIF (show SST ELISA Kits) can inhibit testosterone secretion through the sst2A receptor; local inhibitory action of SRIF (show SST ELISA Kits) is probably autocrine & might involve testosterone-induced increase of sst2 receptor expression in immature Leydig cells [SST2A]
Data demonstrate that urotensin II (show UTS2 ELISA Kits) and urotensin II-related peptide directly activate somatostatin (show SST ELISA Kits) receptors 2 and 5 and thus mimic the effect of somatostatin (show SST ELISA Kits) on its cognate receptors.
Somatostatin (show SST ELISA Kits) directly promoted spontaneous contractions of the circular muscle of macaque intestine via mediation of SSTR2 in myenteric nerve plexus between the longitudinal and the circular muscle.
5-HT(1A (show HTR1A ELISA Kits)), SST (show SST ELISA Kits)(1), and SST (show SST ELISA Kits)(2) receptors mediate nonadrenergic IPSPs in the noncholinergic (VIP (show Vip ELISA Kits)) secretomotor neurons of the submucous plexus of the guinea pig ileum.
Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. The biologic effects of somatostatin are probably mediated by a family of G protein-coupled receptors that are expressed in a tissue-specific manner. SSTR2 is a member of the superfamily of receptors having seven transmembrane segments and is expressed in highest levels in cerebrum and kidney.
, somatostatin receptor type 2
, somatostatin receptor subtype 2
, somatotropin release-inhibiting factor receptor
, somatostatin receptor 2
, somatostatin type 2 receptor
, somatostatin receptor type 2-like